<p>根據 Altman Advisors Inc.最近向證券交易委員會提交的文件，該公司在第三季度收購了強生（NYSE:JNJ - 免費報告）股票的新頭寸。該公司收購了 9,711 股，價值約為 1,574,000 美元。</p>
<p>獲取 <strong>強生</strong> 的提醒：</p>
<ul>
<li>ORIC：與兩家制藥巨頭合作，分析師預計上漲超過 100%</li>
</ul>
<p>其他大型投資者最近也增加或減少了在該公司的股份。Innealta Capital LLC 在第二季度以 27,000 美元的價格購買了強生的新頭寸。Highline Wealth Partners LLC 在第三季度以 31,000 美元的價格購買了強生的新頭寸。Mowery &amp; Schoenfeld Wealth Management LLC 在第三季度將其在強生的持股增加了 58.7%。Mowery &amp; Schoenfeld Wealth Management LLC 目前擁有 246 股強生股票，價值 40,000 美元，此前在該期間又購買了 91 股。Morton Brown Family Wealth LLC 在第三季度將其在強生的持股增加了 400.0%。Morton Brown Family Wealth LLC 目前擁有 250 股強生股票，價值 41,000 美元，此前在該期間又購買了 200 股。最後，MFA Wealth Advisors LLC 在第二季度以 43,000 美元的價格購買了強生的新頭寸。機構投資者持有該公司 69.55% 的股票。</p>
<h2>分析師設定新目標價</h2>
<p>多位研究分析師最近對該公司發表了評論。Guggenheim 將強生的目標價從 156.00 美元上調至 162.00 美元，並在 11 月 6 日的研究報告中給予該股票 “中性” 評級。Wells Fargo &amp; Company 將強生的目標價從 163.00 美元上調至 166.00 美元，並在 10 月 16 日的研究報告中給予該股票 “等權重” 評級。StockNews.com 在 9 月 14 日的研究報告中將強生的評級從 “買入” 上調至 “強力買入”。Daiwa America 在 7 月 23 日的研究報告中將強生的評級從 “強力買入” 下調至 “持有”。最後，加拿大皇家銀行在 10 月 16 日的研究報告中將強生的目標價從 178.00 美元上調至 181.00 美元，並給予該股票 “跑贏大盤” 評級。七位研究分析師對該股票給予了持有評級，八位給予了買入評級，一位給予了強力買入評級。根據 MarketBeat，強生目前的平均評級為 “適度買入”，共識目標價為 175.94 美元。</p>
<ul>
<li>發現 2024 年表現最佳的三隻生物科技 IPO 股票</li>
</ul>
<p><strong>閲讀我們對 JNJ 的最新股票分析</strong></p>
<h2>強生股票表現</h2>
<p>強生股票在週三開盤價為 152.30 美元。該公司的 50 日移動平均價格為 160.83 美元，200 日移動平均價格為 156.19 美元。強生的 12 個月低點為 143.13 美元，12 個月高點為 168.85 美元。該公司的市值為 3666.8 億美元，市盈率為 22.14，PEG 比率為 2.74，貝塔值為 0.53。該公司的流動比率為 1.03，速動比率為 0.79，債務股本比率為 0.45。</p>
<ul>
<li>適合長期投資者的最佳製藥股票：增長與分紅</li>
</ul>
<p>強生（NYSE:JNJ - 獲取免費報告）最近在 10 月 15 日星期二公佈了季度財報。該公司報告季度每股收益為 2.42 美元，超出分析師一致預期的 2.21 美元，超出幅度為 0.21 美元。強生的股本回報率為 35.45%，淨利潤率為 19.14%。該公司在本季度的收入為 224.7 億美元，而分析師預期為 221.7 億美元。去年同期，該公司的每股收益為 2.66 美元。該公司的季度收入同比增長 5.2%。股票研究分析師預測，強生在本年度將發佈 9.93 美元的每股收益。</p>
<h2>強生分紅公告</h2>
<p>該公司最近還披露了季度分紅，將於 12 月 10 日星期二支付。11 月 26 日星期二的股東將獲得每股 1.24 美元的分紅。除息日為 11 月 26 日星期二。這代表着年化分紅為 4.96 美元，分紅收益率為 3.26%。強生的分紅支付比率（DPR）為 71.78%。</p>
<h2>強生內部交易</h2>
<p>在其他消息中，副總裁 Robert J. Decker 在 8 月 30 日星期五的交易中出售了 5,635 股公司的股票。該股票以 165.06 美元的平均價格出售，總交易額為 930,113.10 美元。交易完成後，該副總裁現在直接擁有該公司 18,973 股股票，價值 3,131,683.38 美元。此交易代表其持股減少了 22.90%。該出售在向證券交易委員會的法律文件中披露，該文件可通過 SEC 網站獲取。0.16% 的股票由公司內部人士持有。</p>
<h2>強生公司簡介</h2>
<p>（免費報告）</p>
<p>強生及其子公司在全球範圍內研究、開發、製造和銷售各種醫療保健產品。該公司的創新藥物部門提供多種治療領域的產品，如免疫學，包括類風濕關節炎、銀屑病關節炎、炎症性腸病和銀屑病；傳染病，包括 HIV/AIDS；神經科學，包括情緒障礙、神經退行性疾病和精神分裂症；腫瘤學，包括前列腺癌、血液惡性腫瘤、肺癌和膀胱癌；心血管和代謝，包括血栓、糖尿病和黃斑變性；以及肺動脈高壓，通過零售商、批發商、分銷商、醫院和醫療專業人員進行處方使用。</p>
<h2>閲讀更多</h2>
<ul>
<li>五隻我們更看好的股票，勝過強生</li>
<li>複利及其在投資中的重要性</li>
<li>Williams-Sonoma 股票：買入並永不放手</li>
<li>除了喝咖啡，還有三種投資咖啡的方法</li>
<li>5 只值得買入並長期持有的分紅 ETF</li>
<li>風險承受能力因人而異</li>
<li>伯克希爾購買了 POOL 股票：是時候下手了嗎？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<p>→ [625,000% 收益] – 你準備好迎接下一個山寨幣熱潮了嗎？（來自加密貨幣交換利潤）（廣告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDE2Mg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDE2Mg"/></p>
<h2>你現在應該投資$1,000 在強生嗎？</h2>
<p>在考慮強生之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前買入……而強生並不在名單上。</p>
<p>雖然強生目前在分析師中獲得了 “適度買入” 的評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

強生

<p>Altman Advisors Inc. 在第三季度新建了對強生（NYSE:JNJ）的持倉，購買了 9,711 股，價值約為 574,000 美元。其他機構投資者也調整了他們在該公司的持股。分析師們提高了對 JNJ 的目標價，普遍評級為 “適度買入”，目標價為 94 美元。強生報告的季度每股收益為 2.42 美元，超出預期，並宣佈每股派息 1.24 美元，收益率為 3.26%</p>

<p>Altman Advisors Inc. acquired a new position in shares of Johnson &amp; Johnson (NYSE:JNJ - Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 9,711 shares of the company's stock, valued at approximately $1,574,000.</p>
<div class="lb-trans"><p>根據 Altman Advisors Inc.最近向證券交易委員會提交的文件，該公司在第三季度收購了強生（NYSE:JNJ - 免費報告）股票的新頭寸。該公司收購了 9,711 股，價值約為 1,574,000 美元。</p>
</div><p>Get <strong>Johnson &amp; Johnson</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>強生</strong> 的提醒：</p>
</div><ul>
<li>ORIC: Working with Two Pharma Giants, Analysts See +100% Upside</li>
</ul>
<div class="lb-trans"><ul>
<li>ORIC：與兩家制藥巨頭合作，分析師預計上漲超過 100%</li>
</ul>
</div><p>Other large investors have also recently added to or reduced their stakes in the company. Innealta Capital LLC bought a new position in Johnson &amp; Johnson during the 2nd quarter worth $27,000. Highline Wealth Partners LLC bought a new position in Johnson &amp; Johnson during the 3rd quarter worth $31,000. Mowery &amp; Schoenfeld Wealth Management LLC increased its position in Johnson &amp; Johnson by 58.7% during the 3rd quarter. Mowery &amp; Schoenfeld Wealth Management LLC now owns 246 shares of the company's stock worth $40,000 after buying an additional 91 shares during the period. Morton Brown Family Wealth LLC increased its position in shares of Johnson &amp; Johnson by 400.0% in the third quarter. Morton Brown Family Wealth LLC now owns 250 shares of the company's stock worth $41,000 after purchasing an additional 200 shares during the period. Finally, MFA Wealth Advisors LLC bought a new position in shares of Johnson &amp; Johnson in the second quarter worth $43,000. Institutional investors own 69.55% of the company's stock.</p>
<div class="lb-trans"><p>其他大型投資者最近也增加或減少了在該公司的股份。Innealta Capital LLC 在第二季度以 27,000 美元的價格購買了強生的新頭寸。Highline Wealth Partners LLC 在第三季度以 31,000 美元的價格購買了強生的新頭寸。Mowery &amp; Schoenfeld Wealth Management LLC 在第三季度將其在強生的持股增加了 58.7%。Mowery &amp; Schoenfeld Wealth Management LLC 目前擁有 246 股強生股票，價值 40,000 美元，此前在該期間又購買了 91 股。Morton Brown Family Wealth LLC 在第三季度將其在強生的持股增加了 400.0%。Morton Brown Family Wealth LLC 目前擁有 250 股強生股票，價值 41,000 美元，此前在該期間又購買了 200 股。最後，MFA Wealth Advisors LLC 在第二季度以 43,000 美元的價格購買了強生的新頭寸。機構投資者持有該公司 69.55% 的股票。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新目標價</h2>
</div><p>A number of research analysts recently commented on the company. Guggenheim raised their price target on Johnson &amp; Johnson from $156.00 to $162.00 and gave the stock a &#34;neutral&#34; rating in a research report on Wednesday, November 6th. Wells Fargo &amp; Company raised their price target on Johnson &amp; Johnson from $163.00 to $166.00 and gave the stock an &#34;equal weight&#34; rating in a research report on Wednesday, October 16th. StockNews.com upgraded Johnson &amp; Johnson from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a research report on Saturday, September 14th. Daiwa America cut Johnson &amp; Johnson from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research report on Tuesday, July 23rd. Finally, Royal Bank of Canada raised their price target on Johnson &amp; Johnson from $178.00 to $181.00 and gave the stock an &#34;outperform&#34; rating in a research report on Wednesday, October 16th. Seven research analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Johnson &amp; Johnson presently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $175.94.</p>
<div class="lb-trans"><p>多位研究分析師最近對該公司發表了評論。Guggenheim 將強生的目標價從 156.00 美元上調至 162.00 美元，並在 11 月 6 日的研究報告中給予該股票 “中性” 評級。Wells Fargo &amp; Company 將強生的目標價從 163.00 美元上調至 166.00 美元，並在 10 月 16 日的研究報告中給予該股票 “等權重” 評級。StockNews.com 在 9 月 14 日的研究報告中將強生的評級從 “買入” 上調至 “強力買入”。Daiwa America 在 7 月 23 日的研究報告中將強生的評級從 “強力買入” 下調至 “持有”。最後，加拿大皇家銀行在 10 月 16 日的研究報告中將強生的目標價從 178.00 美元上調至 181.00 美元，並給予該股票 “跑贏大盤” 評級。七位研究分析師對該股票給予了持有評級，八位給予了買入評級，一位給予了強力買入評級。根據 MarketBeat，強生目前的平均評級為 “適度買入”，共識目標價為 175.94 美元。</p>
</div><ul>
<li>Discover the 3 Best-Performing Biotech IPO Stocks of 2024</li>
</ul>
<div class="lb-trans"><ul>
<li>發現 2024 年表現最佳的三隻生物科技 IPO 股票</li>
</ul>
</div><p><strong>Read Our Latest Stock Analysis on JNJ</strong></p>
<div class="lb-trans"><p><strong>閲讀我們對 JNJ 的最新股票分析</strong></p>
</div><h2>Johnson &amp; Johnson Stock Performance</h2>
<div class="lb-trans"><h2>強生股票表現</h2>
</div><p>Shares of JNJ stock opened at $152.30 on Wednesday. The business's 50-day moving average price is $160.83 and its 200-day moving average price is $156.19. Johnson &amp; Johnson has a 12 month low of $143.13 and a 12 month high of $168.85. The firm has a market capitalization of $366.68 billion, a price-to-earnings ratio of 22.14, a PEG ratio of 2.74 and a beta of 0.53. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45.</p>
<div class="lb-trans"><p>強生股票在週三開盤價為 152.30 美元。該公司的 50 日移動平均價格為 160.83 美元，200 日移動平均價格為 156.19 美元。強生的 12 個月低點為 143.13 美元，12 個月高點為 168.85 美元。該公司的市值為 3666.8 億美元，市盈率為 22.14，PEG 比率為 2.74，貝塔值為 0.53。該公司的流動比率為 1.03，速動比率為 0.79，債務股本比率為 0.45。</p>
</div><ul>
<li>Best Pharma Stocks for Long-Term Investors: Growth and Dividends</li>
</ul>
<div class="lb-trans"><ul>
<li>適合長期投資者的最佳製藥股票：增長與分紅</li>
</ul>
</div><p>Johnson &amp; Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, beating analysts' consensus estimates of $2.21 by $0.21. Johnson &amp; Johnson had a return on equity of 35.45% and a net margin of 19.14%. The firm had revenue of $22.47 billion for the quarter, compared to analyst estimates of $22.17 billion. During the same period last year, the firm posted $2.66 earnings per share. The business's revenue for the quarter was up 5.2% on a year-over-year basis. Equities research analysts forecast that Johnson &amp; Johnson will post 9.93 EPS for the current year.</p>
<div class="lb-trans"><p>強生（NYSE:JNJ - 獲取免費報告）最近在 10 月 15 日星期二公佈了季度財報。該公司報告季度每股收益為 2.42 美元，超出分析師一致預期的 2.21 美元，超出幅度為 0.21 美元。強生的股本回報率為 35.45%，淨利潤率為 19.14%。該公司在本季度的收入為 224.7 億美元，而分析師預期為 221.7 億美元。去年同期，該公司的每股收益為 2.66 美元。該公司的季度收入同比增長 5.2%。股票研究分析師預測，強生在本年度將發佈 9.93 美元的每股收益。</p>
</div><h2>Johnson &amp; Johnson Dividend Announcement</h2>
<div class="lb-trans"><h2>強生分紅公告</h2>
</div><p>The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th will be given a dividend of $1.24 per share. The ex-dividend date is Tuesday, November 26th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.26%. Johnson &amp; Johnson's dividend payout ratio (DPR) is 71.78%.</p>
<div class="lb-trans"><p>該公司最近還披露了季度分紅，將於 12 月 10 日星期二支付。11 月 26 日星期二的股東將獲得每股 1.24 美元的分紅。除息日為 11 月 26 日星期二。這代表着年化分紅為 4.96 美元，分紅收益率為 3.26%。強生的分紅支付比率（DPR）為 71.78%。</p>
</div><h2>Insider Transactions at Johnson &amp; Johnson</h2>
<div class="lb-trans"><h2>強生內部交易</h2>
</div><p>In other news, VP Robert J. Decker sold 5,635 shares of the firm's stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $165.06, for a total transaction of $930,113.10. Following the completion of the transaction, the vice president now directly owns 18,973 shares in the company, valued at $3,131,683.38. This trade represents a 22.90 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available through the SEC website. 0.16% of the stock is owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他消息中，副總裁 Robert J. Decker 在 8 月 30 日星期五的交易中出售了 5,635 股公司的股票。該股票以 165.06 美元的平均價格出售，總交易額為 930,113.10 美元。交易完成後，該副總裁現在直接擁有該公司 18,973 股股票，價值 3,131,683.38 美元。此交易代表其持股減少了 22.90%。該出售在向證券交易委員會的法律文件中披露，該文件可通過 SEC 網站獲取。0.16% 的股票由公司內部人士持有。</p>
</div><h2>Johnson &amp; Johnson Company Profile</h2>
<div class="lb-trans"><h2>強生公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Johnson &amp; Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.</p>
<div class="lb-trans"><p>強生及其子公司在全球範圍內研究、開發、製造和銷售各種醫療保健產品。該公司的創新藥物部門提供多種治療領域的產品，如免疫學，包括類風濕關節炎、銀屑病關節炎、炎症性腸病和銀屑病；傳染病，包括 HIV/AIDS；神經科學，包括情緒障礙、神經退行性疾病和精神分裂症；腫瘤學，包括前列腺癌、血液惡性腫瘤、肺癌和膀胱癌；心血管和代謝，包括血栓、糖尿病和黃斑變性；以及肺動脈高壓，通過零售商、批發商、分銷商、醫院和醫療專業人員進行處方使用。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>閲讀更多</h2>
</div><ul>
<li>Five stocks we like better than Johnson &amp; Johnson</li>
<li>Compound Interest and Why It Matters When Investing</li>
<li>Williams-Sonoma Stock: Buy It and Never Let It Go</li>
<li>3 Ways To Invest In Coffee, Other Than Drinking It</li>
<li>5 Dividend ETFs to Buy and Hold Forever</li>
<li>With Risk Tolerance, One Size Does Not Fit All</li>
<li>Berkshire Buys POOL Stock: Is It Time to Take the Plunge?</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過強生</li>
<li>複利及其在投資中的重要性</li>
<li>Williams-Sonoma 股票：買入並永不放手</li>
<li>除了喝咖啡，還有三種投資咖啡的方法</li>
<li>5 只值得買入並長期持有的分紅 ETF</li>
<li>風險承受能力因人而異</li>
<li>伯克希爾購買了 POOL 股票：是時候下手了嗎？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=JNJ"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><p>→ [625,000% Gain] – Are You Ready for the Next Altcoin Boom? (From Crypto Swap Profits)(Ad)</p>
<div class="lb-trans"><p>→ [625,000% 收益] – 你準備好迎接下一個山寨幣熱潮了嗎？（來自加密貨幣交換利潤）（廣告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDE2Mg" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=10162&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Johnson &amp; Johnson right now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在強生嗎？</h2>
</div><p>Before you consider Johnson &amp; Johnson, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮強生之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson &amp; Johnson wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前買入……而強生並不在名單上。</p>
</div><p>While Johnson &amp; Johnson currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然強生目前在分析師中獲得了 “適度買入” 的評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Altman Advisors Inc. 在強生公司（紐約證券交易所代碼：JNJ）進行了新的 157 萬美元投資